Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 360 matching trials from the live ClinicalTrials.gov search.
Filters: "chemoradiation" Condition: Head and Neck Cancer Clear all
Completed Phase 2 Interventional Results available

Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer

NCT00713219
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
IMRT, cetuximab, docetaxel
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Omaha, Nebraska • Basking Ridge, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer

NCT00238147
View directory record Official record
Conditions
Esophageal Cancer
Interventions
capecitabine, carboplatin, docetaxel, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

NCT01711658
View directory record Official record
Conditions
Non-HPV Locally Advanced Head and Neck Cancer
Interventions
IMRT, Cisplatin, placebo, Lapatinib
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated Early Phase 1 Interventional

Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

NCT03578432
View directory record Official record
Conditions
Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer
Interventions
Everolimus, Laboratory Biomarker Analysis, Survey Administration
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 14, 2026, 10:02 PM EDT
Withdrawn Not applicable Interventional

Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

NCT05099952
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Counseling, Educational Intervention, Electronic Health Record Review, Medical Device Usage and Evaluation, Questionnaire Administration
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Not applicable Interventional Results available

Low-Level Laser Therapy for Prevention of Oral Mucositis

NCT02723604
View directory record Official record
Conditions
Mucositis
Interventions
Low Level Laser Therapy
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 14, 2026, 10:02 PM EDT
Active, not recruiting Not applicable Interventional

Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

NCT02945631
View directory record Official record
Conditions
Locally Advanced HPV Positive Oropharynx Cancer
Interventions
PTV56, PTV50.4
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

NCT02764593
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Nivolumab, Cisplatin, Cetuximab, IMRT
Drug · Radiation
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
11
States / cities
Palo Alto, California • Orlando, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

NCT00578071
View directory record Official record
Conditions
Cancer of the Esophagus
Interventions
Panitumumab, Capecitabine, Oxaliplatin, Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Brian Czito
Other
Eligibility
18 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

NCT03107182
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
Drug · Procedure · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck

NCT00084318
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, docetaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
160
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 14, 2026, 10:02 PM EDT
Active, not recruiting Phase 2 Interventional

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT01154920
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Paclitaxel, Carboplatin, Cetuximab, Docetaxel, Cisplatin, Fluorouracil, Radiotherapy (RT), Chemotherapy
Drug · Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00551759
View directory record Official record
Conditions
Esophageal Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Cetuximab, Docetaxel, Surgery, Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
109
States / cities
Lewes, Delaware • Newark, Delaware • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

De-Escalation Therapy for Human Papillomavirus Negative Disease

NCT03944915
View directory record Official record
Conditions
Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
Carboplatin, Paclitaxel, Nivolumab, Radiation, Hydroxyurea Pill, 5-fluorouracil, Filgrastim Injection, Cisplatin
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 2 Interventional Results available

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

NCT04752384
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Buprenorphine, Tramadol, Oral Mucositis (OM) Pain App
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated Phase 1 Interventional

Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT00080028
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2007 · Synced Oct 14, 2026, 10:02 PM EDT
Completed No phase listed Observational

Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis

NCT01252498
View directory record Official record
Conditions
Cancer of the Head and Neck, Radiotherapy
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response

NCT00994201
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DCE-MRI, DW-MRI and MRS
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 25, 2016 · Synced Oct 14, 2026, 10:02 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
Interventions
Best Practice, Biospecimen Collection, Cisplatin, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, MnSOD Mimetic BMX-001, Placebo Administration, Questionnaire Administration
Other · Procedure · Drug + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
153
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT03129061
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Not applicable Interventional Results available

FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer

NCT01243619
View directory record Official record
Conditions
Esophageal Cancer
Interventions
3'-deoxy-3'-(18) F-fluorothymidine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 14, 2026, 10:02 PM EDT
Completed Not applicable Interventional

Pre-treatment Exercises Versus Post-treatment Exercises for Dysphagia

NCT00584129
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pre-treatment swallowing exercises, Post-treatment swallowing exercises.
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 14, 2026, 10:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Symptom Burden in Head and Neck Cancer

NCT01219673
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Placebo, Armodafinil, Minocycline, Bupropion
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 14, 2026, 10:02 PM EDT
Active, not recruiting Phase 2 Interventional

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

NCT05318027
View directory record Official record
Conditions
Lung Cancer, Gastrointestinal Cancer, Head and Neck Cancer
Interventions
ChatBot
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 14, 2026, 10:02 PM EDT